tbuckley/cabot-search huggingface dataset:
Emodin attenuates severe acute pancreatitis-associated acute lung injury by suppressing pancreatic exosome-mediated alveolar macrophage activation
Authors: Qian Hu, Jiaqi Yao, Xiajia Wu, Juan Li, Guixiang Li, Wenfu Tang, Jingping Liu, Meihua Wan
Journal: Acta Pharmaceutica Sinica B (2021)

Severe acute pancreatitis-associated acute lung injury (SAP-ALI) is a serious disease associated with high mortality. Emodin has been applied to alleviate SAP-ALI; however, the mechanism remains unclear. We report that the therapeutic role of emodin in attenuating SAP-ALI is partly dependent on an exosomal mechanism. SAP rats had increased levels of plasma exosomes with altered protein contents compared to the sham rats. These infused plasma exosomes tended to accumulate in the lungs and promoted the hyper-activation of alveolar macrophages and inflammatory damage. Conversely, emodin treatment decreased the plasma/pancreatic exosome levels in the SAP rats. Emodin-primed exosomes showed less pro-inflammatory effects in alveolar macrophages and lung tissues than SAP exosomes. In detail, emodin-primed exosomes suppressed the NF-κB pathway to reduce the activation of alveolar macrophage and ameliorate lung inflammation by regulating PPARγ pathway, while these effects were amplified/abolished by PPARγ agonist/antagonist. Blockage of pancreatic acinar cell exosome biogenesis also exhibited suppression of alveolar macrophage activation and reduction of lung inflammation. This study suggests a vital role of exosomes in participating inflammation-associated organ-injury, and indicates emodin can attenuate SAP-ALI by reducing the pancreatic exosome-mediated alveolar macrophage activation.
TCT-439 Incidence, Characteristics, and Outcomes of Early Perioperative Graft Failure Following Coronary Artery Bypass Grafting
Authors: Waiel Abusnina, Fahad Alqahtani, Ahmad Al-Abdouh, Mostafa Mostafa, Qais Radaideh, Yasar Sattar, Khagendra Dahal
Journal: Journal of the American College of Cardiology (2021)
TCT-289 Efficacy and Safety of More Potent Platelet P2Y12 Inhibitors Versus Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention: A Meta-Analysis
Authors: Ghulam Murtaza, Bhaskar Bhardwaj, Kalyan Chitturi, Arun Kumar, Kul Aggarwal
Journal: Journal of the American College of Cardiology (2021)
Truncated titin proteins in dilated cardiomyopathy
Authors: Quentin McAfee, Christina Yingxian Chen, Yifan Yang, Matthew A. Caporizzo, Michael Morley, Apoorva Babu, Sunhye Jeong, Jeffrey Brandimarto, Kenneth C. Bedi, Emily Flam, Joseph Cesare, Thomas P. Cappola, Kenneth Margulies, Benjamin Prosser, Zolt Arany
Journal: Science Translational Medicine (2021)

Truncating mutations in TTN result in both truncated titin proteins and reduced full-length titin in patient hearts.
TCT-328 Improvement of TAVR Patient Outcome
Authors: Won-Keun Kim, Felix Woitek, Philipp Kiefer, Florian Schlotter, Georg Stachel, Sergey Leontyev, Christian Hamm, David Holzhey, Helge Möllmann, Michael Borger, Thomas Walther, Axel Linke, Norman Mangner, Stephan Haussig
Journal: Journal of the American College of Cardiology (2021)
TCT-303 The Influence of Obesity on Coronary Artery Disease and Clinical Outcomes in the ADVANCE Registry
Authors: Angela Lowenstern, Hidenobu Takagi, Nicholas Ng, Jennifer Rymer, Lynne Koweek, Pamela Douglas, Jessica Duran, Mark Rabbat, Kavitha Chinnaiyan, Daniel Berman, Bernard De Bruyne, Jeroen Bax, Takashi Akasaka, Tetsuya Amano, Koen Nieman, Campbell Rogers, Hironori Kitabata, Niels Peter Rønnow Sand, Tomohiro Kawasaki, Sarah Mullen, Hitoshi Matsuo, Bjarne Norgaard, Manesh Patel, Jonathon Leipsic, Melissa Daubert
Journal: Journal of the American College of Cardiology (2021)
TCT-327 A Prospective, Randomized Trial of a Novel Localized Abluminal Groove With Low-Dose Sirolimus-Eluting and Biodegradable Polymer Stent Compared to a Durable Polymer-Based Everolimus-Eluting Stent in Patients With Coronary Artery Chronic Total Occlusions: The TARGET CTO Trial
Authors: Geng Wang, Ruiyan Zhang, Shaoliang Chen, Jianan Wang, Yitong Ma, Zhiqi Sun, Wen Lu, Yawei Xu, Xue Li, Fucheng Sun, Yaling Han
Journal: Journal of the American College of Cardiology (2021)
Surface structure change properties: Auto-soft bionic fibrous membrane in reducing postoperative adhesion
Authors: Shanshan Xu, Chenhong Wang, Ruoqing Mao, Xiaoyu Liang, Heran Wang, Zhenyu Lin, Jiangxue Li, Shilin Li, Jipeng Jiang, Tongshuo Zhang, Yongfu Ma, Yang Liu, Charles C. Han, Ying Liu
Journal: Bioactive Materials (2021)

Peritoneal adhesion is the most common adverse effect following abdominal surgery or inflammation. The occurrence in clinical trials has been successfully reduced using barriers. However, the shortcomings of frequently used adhesion barriers, such as rapid degradation rate of gel barrier and inadequate operation ability of solid barrier, cannot be ignored. In this study, a fibrous membrane with an ECM-like structure was prepared. The adhesion properties were reduced significantly by changing the surface structure. The fibrous membrane caused less inflammatory response and much less peripheral adhesion and intestinal obstruction compared to the casting film and the commercial film with smooth surface, though with the same components. Because of the auto-soft bionic structure and similarity in the mechanical modulus of the tissues, the fibrous membrane was more flexible when it adhered to the tissues, showed excellent effectiveness and biocompatibility. In addition to the rat and miniature pig models, a randomized, placebo-controlled, and multicenter clinical pilot study with 150 patients confirmed that because of its flexibility, biodegradability, and similarity to mechanical modulus and structure with tissues involved, the fibrous membrane served as a favorable implant for preventing post-operation adhesion.
Engineered Bacteria Enhance Immunotherapy and Targeted Therapy through Stromal Remodeling of Tumors
Authors: Shindu C. Thomas, Tushar Madaan, Nitin S. Kamble, Nabil A. Siddiqui, Giovanni M. Pauletti, Nalinikanth Kotagiri
Journal: Advanced Healthcare Materials (2021)

Desmoplastic solid tumors are characterized by the rapid build-up of extracellular matrix (ECM) macromolecules, such as hyaluronic acid (HA). The resulting physiological barrier prevents the infiltration of immune cells and also impedes the delivery of anticancer agents. The development of a hypervesiculating Escherichia coli Nissle (ΔECHy) based tumor targeting bacterial system capable of distributing a fusion peptide, cytolysin A (ClyA)-hyaluronidase (Hy) via outer membrane vesicles (OMVs) is reported. The capability of targeting hypoxic tumors, manufacturing recombinant proteins in situ and the added advantage of an on-site OMV based distribution system makes the engineered bacterial vector a unique candidate for peptide delivery. The HA degrading potential of Hy for stromal modulation is combined with the cytolytic activity of ClyA followed by testing it within syngeneic cancer models. ΔECHy is combined with immune checkpoint antibodies and tyrosine kinase inhibitors (TKIs) to demonstrate that remodeling the tumor stroma results in the improvement of immunotherapy outcomes and enhancing the efficacy of biological signaling inhibitors. The biocompatibility of ΔECHy is also investigated to show that the engineered bacteria are effectively cleared, elicit minimal inflammatory and immune responses, and therefore could be a reliable candidate as a live biotherapeutic.
Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study
Authors: Pascal Joly, André Gillibert, Gérôme Bohelay, Karen Aouar, Saskia Ingen-Housz-Oro, Christophe Bedane, Clémence Lepelletier, Emmanuelle Tancrède Bohin, Manuelle Viguier, Nicolas Dupin, Sebastien Debarbieux, Denis Jullien, Gaelle Quereux, Cécile Morice, Antoine Mahe, Catherine Michel, Noemie Litrowski, Géraldine Jeudy, Marie Aleth Richard, Catherine Picard, Olivier Chosidow, Anne-Pham Ledard, Vivien Hebert, Sophie Duvert-Lehembre, Nadège Cordel, Marina Alexandre, Christelle Le Roux-Villet, Frédéric Caux
Journal: Journal of the American Academy of Dermatology (2021)
TCT-472 Deploying a Custom STEMI Transfer Application in a Large Health Care System to Improve Cross-Team Work Flow
Authors: Haydee Garcia, Jennifer Siller, Julianna Bastone, Kevin Chason, Michael Redlener, Andriy Vengrenyuk, Matthew Bai, Abraham Warshaw, Atul Kukar, Bernadette Springer, Derek Pineda, Parasuram Krishnamoorthy, Joseph Sweeny, Jeffrey Bander, Nitin Barman, Annapoorna Kini
Journal: Journal of the American College of Cardiology (2021)
NICE understates role of exercise and CBT in managing ME/CFS, say medical leaders
Authors: Zosia Kmietowicz
Journal: BMJ (2021)

Medical leaders have questioned the updated guideline from the National Institute for Health and Care Excellence (NICE) on myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) for downplaying the importance of activity and exercise in managing the condition.

They say that the guideline understates the connection between mental and physical health, does not reflect how exercise therapy is used in practice, and fails to represent the positive discussions that leaders have had with patient groups.

The guideline was finally published on 29 October,1 after NICE delayed its publication because three members of the committee overseeing its production resigned in August and royal colleges raised concerns about the recommendations and processes used in developing it.2

NICE said that graded exercise therapy (GET) should no longer be used to treat ME/CFS but that exercise programmes could still …
EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults
Authors: Didier Frappaz, Girish Dhall, Matthew J Murray, Stuart Goldman, Cecile Faure Conter, Jeffrey Allen, Rolf Dieter Kortmann, Daphne Haas-Kogen, Giovanni Morana, Jonathan Finlay, James C Nicholson, Ute Bartels, Mark Souweidane, Stefan Schönberger, Alexandre Vasiljevic, Patricia Robertson, Assunta Albanese, Claire Alapetite, Thomas Czech, Chin C Lau, Patrick Wen, David Schiff, Dennis Shaw, Gabriele Calaminus, Eric Bouffet
Journal: Neuro-Oncology (2021)

The incidence of intracranial germ cell tumors (iGCT) is much lower in European and North American (E&NA) than in Asian population. However, E&NA cooperative groups have simultaneously developed with success treatment strategies with specific attention paid to long-term sequelae. Neurological sequelae may be reduced by establishing a diagnosis with an endoscopic biopsy and/or cerebrospinal fluid (CSF) and/or serum analysis, deferring the need to perform a radical surgery. Depending on markers and/or histological characteristics, patients are treated as either germinoma or non-germinomatous germ cell tumors (NGGCT). Metastatic disease is defined by a positive CSF cytology and/or distant drops in craniospinal MRI. The combination of surgery and/or chemotherapy and radiation therapy is tailored according to grouping and staging. With more than 90% 5-year event-free survival (EFS), localized germinomas can be managed without aggressive surgery, and benefit from chemotherapy followed by whole ventricular irradiation with local boost. Bifocal germinomas are treated as non-metastatic entities. Metastatic germinomas may be cured with craniospinal irradiation. With a 5-year EFS over 70%, NGGCT benefit from chemotherapy followed by delayed surgery in case of residual disease, and some form of radiotherapy. Future strategies will aim at decreasing long-term side effects while preserving high cure rates.
Predicting Factors of Humoral Response to Pfizer BNT 162b2 in Hemodialysis Patients
Authors: Rui A. Duarte, Cátia R. Figueiredo, Marisa Roldão, Ivan A. Luz, Francisco Ferrer, Hernâni M. Gonçalves, Flora Sofia
Journal: Journal of the American Society of Nephrology (2021)

Duarte, Rui A.; Figueiredo, Cátia R.; Roldão, Marisa; Luz, Ivan A.; Ferrer, Francisco; Gonçalves, Hernâni M.; Sofia, Flora Author Information
TCT-250 Differential Intensity of Lipid-Lowering Therapy Among Patients With and Without Previous Coronary Revascularization—Insights From GOULD
Authors: Benjamin Peterson, Deepak Bhatt, Christie Ballantyne, James de Lemos, Jason Exter, Shushama Alam, Naishu Kui, Mikhail Kosiborod, Christopher Cannon
Journal: Journal of the American College of Cardiology (2021)
TCT-409 Unsupervised Clustering of Structural and Functional Echocardiographic Parameters Identifies a High-Risk Phenotype Among Patients With Severe Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair
Authors: Teresa Trenkwalder, Mark Lachmann, Héctor Alvarez Covarrubias, Elena Rippen, Friederike Schürmann, Antonia Presch, Céline Ruff, Moritz von Scheidt, Petra Hoppmann, Christian Kupatt, Patrick Mayr, Heribert Schunkert, Adnan Kastrati, Michael Joner, Erion Xhepa
Journal: Journal of the American College of Cardiology (2021)
Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases
Authors: Li Wang, Jiajia Li, Li‐jun Di
Journal: Medicinal Research Reviews (2021)

Abstract Glycogen synthase kinase‐3 (GSK3) is a highly evolutionarily conserved serine/threonine protein kinase first identified as an enzyme that regulates glycogen synthase (GS) in response to insulin stimulation, which involves GSK3 regulation of glucose metabolism and energy homeostasis. Both isoforms of GSK3, GSK3α, and GSK3β, have been implicated in many biological and pathophysiological processes. The various functions of GSK3 are indicated by its widespread distribution in multiple cell types and tissues. The studies of GSK3 activity using animal models and the observed effects of GSK3‐specific inhibitors provide more insights into the roles of GSK3 in regulating energy metabolism and homeostasis. The cross‐talk between GSK3 and some important energy regulators and sensors and the regulation of GSK3 in mitochondrial activity and component function further highlight the molecular mechanisms in which GSK3 is involved to regulate the metabolic activity, beyond its classical regulatory effect on GS. In this review, we summarize the specific roles of GSK3 in energy metabolism regulation in tissues that are tightly associated with energy metabolism and the functions of GSK3 in the development of metabolic disorders. We also address the impacts of GSK3 on the regulation of mitochondrial function, activity and associated metabolic regulation. The application of GSK3 inhibitors in clinical tests will be highlighted too. Interactions between GSK3 and important energy regulators and GSK3‐mediated responses to different stresses that are related to metabolism are described to provide a brief overview of previously less‐appreciated biological functions of GSK3 in energy metabolism and associated diseases through its regulation of GS and other functions.
TCT-395 Diagnostic Performance of 3D Quantitative Coronary Angiography Vessel FFR With Diastolic Pressure Ratio: A Pooled Analysis of the FAST EXTEND and FAST II Studies
Authors: Alessandra Scoccia, Tara Neleman, Mariusz Tomaniak, Kaneshka Masdjedi, Frederik Groenland, Jurgen Ligthart, Nicolas Van Mieghem, Ernest Spitzer, Joost Daemen
Journal: Journal of the American College of Cardiology (2021)
TCT-449 Impact of Angiotensin Receptor Neprilysin Inhibitors in the Selection and Outcomes of Candidates for Mitral Edge-to-Edge Therapy
Authors: Alejandro Barrero, Fernando Carrasco, Tomás Benito-González, Isaac Pascual, Dabit Arzamendi, Rodrigo Estevez-Loureiro, Luis Nombela-Franco, Manuel Pan, Xavier Freixa, Belen Cid Alvarez, Angel Sanchez-Recalde, Abel Andres Morist, Ignacio Cruz-Gonzalez, Ana Serrador, Ignacio Amat-Santos
Journal: Journal of the American College of Cardiology (2021)
Thin-cap Fibroatheromaの空間分布に対するスタチン療法の影響-連続三次元光干渉断層法研究
Authors: Nakamura Takeshi, Okamura Takayuki, Yamada Jutaro, Nao Tomoko, Oda Tetsuro, Mochizuki Mamoru, Tateishi Hiroki, Shiraishi Kozo, Maeda Takao, Nakashima Tadamitsu, Nishimura Shigehiko, Yano Masafumi
Journal: Circulation (2014)
TCT-21 Thrombolysis in Spontaneous Coronary Artery Dissection: Angiographic Findings and Clinical Outcomes
Authors: Cameron McAlister, Rohit Samuel, Mesfer Alfadhel, Thomas Nestelberger, Andrew Starovoytov, Johandra Argote, Tejana Grewal, Eve Aymong, Jacqueline Saw
Journal: Journal of the American College of Cardiology (2021)
TCT-167 Utilization Rates and In-Hospital Outcomes Associated With Intravascular Imaging–Guided PCI in the USA: An Analysis of the NCDR CathPCI Registry
Authors: Zachary Wegermann, Rebecca Young, Amit Amin, Robert Riley, Akiko Maehara, Daniel Wojdyla, Eric Secemsky, Ziad Ali, Ajay Kirtane, Tracy Wang, Robert Yeh, Sunil Rao
Journal: Journal of the American College of Cardiology (2021)
Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA)
Authors: Bradley J Petek, Nathaniel Moulson, Aaron L Baggish, Stephanie A Kliethermes, Manesh R Patel, Timothy W Churchill, Kimberly G Harmon, Jonathan A Drezner
Journal: British Journal of Sports Medicine (2021)

To assess the prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms in young competitive athletes following SARS-CoV-2 infection.This observational cohort study from the Outcomes Registry for Cardiac Conditions in Athletes included 3597 US collegiate athletes after SARS-CoV-2 infection. Clinical characteristics, advanced diagnostic testing and SARS-CoV-2-associated sequelae were compared between athletes with persistent symptoms >3 weeks, exertional symptoms on return to exercise and those without persistent or exertional symptoms.Among 3597 athletes (mean age 20 years (SD, 1 year), 34% female), data on persistent and exertional symptoms were reported in 3529 and 3393 athletes, respectively. Persistent symptoms >3 weeks were present in 44/3529 (1.2%) athletes with 2/3529 (0.06%) reporting symptoms >12 weeks. Exertional cardiopulmonary symptoms were present in 137/3393 (4.0%) athletes. Clinical evaluation and diagnostic testing led to the diagnosis of SARS-CoV-2-associated sequelae in 12/137 (8.8%) athletes with exertional symptoms (five cardiac involvement, two pneumonia, two inappropriate sinus tachycardia, two postural orthostatic tachycardia syndrome and one pleural effusion). No SARS-CoV-2-associated sequelae were identified in athletes with isolated persistent symptoms. Of athletes with chest pain on return to exercise who underwent cardiac MRI (CMR), 5/24 (20.8%) had probable or definite cardiac involvement. In contrast, no athlete with exertional symptoms without chest pain who underwent CMR (0/20) was diagnosed with probable or definite SARS-CoV-2 cardiac involvement.Collegiate athletes with SARS-CoV-2 infection have a low prevalence of persistent or exertional symptoms on return to exercise. Exertional cardiopulmonary symptoms, specifically chest pain, warrant a comprehensive evaluation.
Freezing duty on alcohol undermines plans for healthier tax system, say experts
Authors: Adrian O’Dowd
Journal: BMJ (2021)

Alcohol misuse experts have warned that the government’s reforms of alcohol taxes are undermined by the decision to freeze alcohol duty for another year, which they said could encourage more alcohol consumption.

The government unveiled plans to overhaul the current alcohol duty system in its autumn budget,1 claiming it will tax stronger types of alcohol more heavily to make the system fairer and healthier.

In his budget speech, Chancellor of the Exchequer Rishi Sunak said the current system was “outdated, complex, and full of historical anomalies,” and the reforms would see drinks taxed in direct proportion to their alcohol content.

The new approach would involve reducing the number of bands at which different duties …
Evaluating Tradeoffs between Autonomy and Wellbeing in Supported Decision Making
Authors: Walter Veit, Brian D. Earp, Heather Browning, Julian Savulescu
Journal: The American Journal of Bioethics (2021)

A core challenge for contemporary bioethics is how to address the tension between respecting an individual’s autonomy and promoting their wellbeing when these ideals seem to come into conflict (Not...
Activin beta E (INHBE), a RASSF1A target gene is downregulated in hepatocellular carcinoma
Authors: Chit Chow, Nathalie Wong, Ka Fai To, Kwok Wai Lo
Journal: Cancer Research (2007)

3662  Inactivation of RASSF1A tumor suppressor is common in a variety of human cancers including nasopharyngeal carcinoma (NPC) and hepatocellular carcinoma (HCC). By microarray analysis, we have demonstrated that the expression of Activin beta E (INHBE), a member of TGF-β superfamily is upregulated in RASSF1A-transfected NPC cells. Although the downstream pathway of INHBE is still unknown, it is suspected that INHBE-signaling pathway is tumor suppressive based on the similarity to other known activins. In this study, we have investigated the role of INHBE in the development of HCC in which RASSF1A is frequently silenced by promoter hypermethylation. To examine the Activin beta E expression in primary tumors, immunohistochemical staining was performed on a HCC tissue micoarray containing 174 pairs of formalin-fixed, paraffin-embedded primary HCC tumor and adjacent non-malignant liver. Antibody against peptide corresponding to amino acid residues 116-126 of human activin beta E was raised in rabbit and purified by peptide-specific purification. In non-malignant hepatocyte adjacent to primary HCC, moderate to high cytoplasmic staining of Activin beta E was shown. We found that Activin beta E expression was highly reduced in 118 out of 174 primary HCCs (67.8%). Among these cases, 23 (13%) showed completed loss of Activin beta E expression when compared with corresponding non-malignant hepatocyte. The association of INHBE and RASSF1A expression in these cases has been determined. The tumor suppressor properties of INHBE and its expression in primary HCC were studied. Upregulation of INHBE expression was proven in RASSF1A-transfected HCC cell lines. Although activin family members were shown to be ligands acting through Smads, we found that both Smad 1/5/8 and Smad 2/3 were not activated by ectopically expressed INHBE. Nevertheless, significant growth inhibition was demonstrated in the transient-transfected HCC cells overexpressing INHBE. Our study suggested that INHBE is a growth inhibiting gene which mediates the tumor suppression effect of RASSF1A in HCC.
Abstract 11473: Sestrin2-mTORC1 Signaling Mediates Myocardial Endoplasmic Reticulum Stress During Ischemia/reperfusion
Authors: Xuan Li, Di Ren, Jingwen Zhang, Jia Liu, Ji Li
Journal: Circulation (2019)

Introduction: Endoplasmic reticulum (ER) stress is emerged as a mediator during myocardial ischemia and reperfusion (I/R). We have found that Sestrin2 (Sesn2) acts as an endogenous inhibitor of the...